Drugs with expired main patents
1. Abilify patent expiration
ABILIFY's oppositions filed in EPO
ABILIFY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(2 years ago) | |
| US5006528 | OTSUKA | Carbostyril derivatives |
Oct, 2014
(10 years ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(2 years ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(2 years ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(11 months ago) | |
|
US8642600 (Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(2 years ago) | |
| US8518421 | OTSUKA | Flashmelt oral dosage formulation |
Jan, 2021
(3 years ago) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(2 years from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(1 year, 7 months from now) | |
|
US5006528 (Pediatric) | OTSUKA | Carbostyril derivatives |
Apr, 2015
(9 years ago) | |
|
US8518421 (Pediatric) | OTSUKA | Flashmelt oral dosage formulation |
Jul, 2021
(3 years ago) | |
| US9358207 | OTSUKA | Flashmelt oral dosage formulation |
Apr, 2020
(4 years ago) | |
|
US8642760 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(1 year, 8 months ago) | |
|
US8580796 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(1 year, 8 months ago) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(6 months ago) | |
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(5 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: Treatment of irritability associated with autistic disorder; Treatment of schizophrenia including maintaining stability in patients with schizophrenia; Treatment of schizophrenia; Treatment of major d...
Dosage: TABLET; TABLET, ORALLY DISINTEGRATING
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
2. Abilify Maintena Kit patent expiration
ABILIFY MAINTENA KIT's oppositions filed in EPO
ABILIFY MAINTENA KIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5006528 | OTSUKA PHARM CO LTD | Carbostyril derivatives |
Oct, 2014
(10 years ago) | |
| US8993761 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
| US8399469 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5006528 (Pediatric) | OTSUKA PHARM CO LTD | Carbostyril derivatives |
Apr, 2015
(9 years ago) | |
| US9089567 | OTSUKA PHARM CO LTD | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(2 years ago) | |
| US8759351 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(1 year, 4 months ago) | |
| US8338428 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(1 year, 4 months ago) | |
| US5006528 | OTSUKA PHARM CO LTD | Carbostyril derivatives |
Apr, 2015
(9 years ago) | |
| US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(9 years from now) | |
| US8338427 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Mar, 2025
(2 months from now) | |
| US11400087 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(8 years from now) | |
| US10980803 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(8 years from now) | |
| US11154553 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(8 years from now) | |
| US7807680 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(2 months ago) | |
| US8722679 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(2 months ago) | |
| US11648347 | OTSUKA PHARM CO LTD | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient |
Apr, 2034
(9 years from now) | |
| US8030313 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(2 months ago) | |
| US11344547 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Tr...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage
ABILIFY MAINTENA KIT family patents
3. Abilify Mycite Kit patent
expiration
ABILIFY MYCITE KIT's oppositions filed in EPO
ABILIFY MYCITE KIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9787511 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(2 years ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(11 months ago) | |
| US9270503 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | |
| US9577864 | OTSUKA | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
Oct, 2033
(8 years from now) | |
| US10097388 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(2 years ago) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(2 years from now) | |
| US8674825 | OTSUKA | Pharma-informatics system |
Apr, 2029
(4 years from now) | |
| US8956288 | OTSUKA | In-body power source having high surface area electrode |
Jul, 2029
(4 years from now) | |
| US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(5 years from now) | |
| US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(5 years from now) | |
| US8945005 | OTSUKA | Controlled activation ingestible identifier |
Aug, 2029
(4 years from now) | |
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(8 years from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(1 year, 7 months from now) | |
| US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(2 years from now) | |
| US9433371 | OTSUKA | In-body device with virtual dipole signal amplification |
Sep, 2029
(4 years from now) | |
| US9149577 | OTSUKA | Body-associated receiver and method |
Dec, 2029
(4 years from now) | |
| US7978064 | OTSUKA | Communication system with partial power source |
Sep, 2026
(1 year, 8 months from now) | |
| US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(3 years from now) | |
| US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(5 years from now) | |
| US11229378 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(6 years from now) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(6 months ago) | |
| US8718193 | OTSUKA | Active signal processing personal health signal receivers |
Dec, 2029
(4 years from now) | |
| US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(5 years from now) | |
| US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(5 years from now) | |
| US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(5 years from now) | |
| US9060708 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(4 years from now) | |
| US10441194 | OTSUKA | Ingestible event marker systems |
Jul, 2029
(4 years from now) | |
| US9320455 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(6 years from now) | |
| US9258035 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(4 years from now) | |
| US11476952 | OTSUKA | Pharma-informatics system |
Apr, 2026
(1 year, 4 months from now) | |
| US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(7 years from now) | |
| US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(5 years from now) | |
| US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Treatment of schizophrenia; Adjunctive treatment of ma...
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
4. Adasuve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9687487 | ALEXZA PHARMS | Aerosol forming device for use in inhalation therapy |
Oct, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9440034 | ALEXZA PHARMS | Drug condensation aerosols and kits |
Oct, 2021
(3 years ago) | |
| US7090830 | ALEXZA PHARMS | Drug condensation aerosols and kits |
Oct, 2021
(3 years ago) | |
| US7585493 | ALEXZA PHARMS | Thin-film drug delivery article and method of use |
Oct, 2021
(3 years ago) | |
| US7052679 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Mar, 2022
(2 years ago) | |
| US7078020 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(3 years ago) | |
| US7601337 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(3 years ago) | |
| US8074644 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(3 years ago) | |
| US8955512 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(3 years ago) | |
| US6716416 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
May, 2022
(2 years ago) | |
| US9439907 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(3 years ago) | |
| US8173107 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(3 years ago) | |
| US8235037 | ALEXZA PHARMS | Drug condensation aerosols and kits |
Oct, 2021
(3 years ago) | |
| US8991387 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(7 months ago) | |
| US9370629 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(7 months ago) | |
| US8387612 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
Oct, 2026
(1 year, 10 months from now) | |
| US7458374 | ALEXZA PHARMS | Method and apparatus for vaporizing a compound |
Aug, 2024
(4 months ago) | |
| US7537009 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2024
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 21, 2015 |
Drugs and Companies using LOXAPINE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: Adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults
Dosage: POWDER
More Information on Dosage
ADASUVE family patents
5. Addyi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7420057 | SPROUT PHARMS | Stable polymorph of flibanserin |
Aug, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8227471 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
May, 2023
(1 year, 7 months ago) | |
| US9468639 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
Oct, 2022
(2 years ago) | |
| US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 18, 2020 |
Drugs and Companies using FLIBANSERIN ingredient
NCE-1 date: 19 August, 2019
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET
More Information on Dosage
ADDYI family patents
6. Adlyxin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45313 | SANOFI-AVENTIS US | Exendin variant peptides |
Jul, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9821032 | SANOFI-AVENTIS US | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(7 years from now) | |
| US10201663 | SANOFI-AVENTIS US | Assembly for a drug delivery device |
Mar, 2034
(9 years from now) | |
| US8475414 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(6 years from now) | |
| US9308329 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(6 years from now) | |
| US8915888 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Jun, 2030
(5 years from now) | |
| US9981013 | SANOFI-AVENTIS US | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
Aug, 2030
(5 years from now) | |
| US9408893 | SANOFI-AVENTIS US | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
Aug, 2032
(7 years from now) | |
| US9084853 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Oct, 2031
(6 years from now) | |
| US9855388 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Apr, 2029
(4 years from now) | |
| US9072836 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Mar, 2032
(7 years from now) | |
| US9440029 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Jan, 2032
(7 years from now) | |
| US9511193 | SANOFI-AVENTIS US | Assembly and indicator for a drug delivery device |
Jan, 2032
(7 years from now) | |
| US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(5 years from now) | |
| US10028910 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
Nov, 2030
(5 years from now) | |
| US8882721 | SANOFI-AVENTIS US | Drive assembly suitable for use in a drug delivery device and drug delivery device |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: Combination treatment with insulin glargine with or without metformin for improvement of glycemic control in type 2 diabetes mellitus patients; Improvement in glycemic control in type 2 diabetes melli...
Dosage: SOLUTION
More Information on Dosage
ADLYXIN family patents
7. Aggrastat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6136794 | MEDICURE | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
Jan, 2019
(5 years ago) | |
| US5978698 | MEDICURE | Angioplasty procedure using nonionic contrast media |
Oct, 2017
(7 years ago) | |
| US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(8 years ago) | |
| US5972967 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(8 years ago) | |
| US5965581 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(8 years ago) | |
| US6770660 | MEDICURE | Method for inhibiting platelet aggregation |
May, 2023
(1 year, 7 months ago) | |
Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 May, 1998
Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...
Dosage: SOLUTION; INJECTABLE
How can I launch a generic of AGGRASTAT before it's drug patent expiration?
More Information on Dosage
AGGRASTAT family patents
8. Arcapta Neohaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
| US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
Drugs and Companies using INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 01 July, 2011
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
Dosage: POWDER
More Information on Dosage
ARCAPTA NEOHALER family patents
9. Arnuity Ellipta patent expiration
ARNUITY ELLIPTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(2 years from now) | |
| US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
| US7629335 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(5 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(4 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(2 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(5 years from now) | |
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 20, 2017 |
| New Patient Population(NPP) | May 17, 2021 |
| New Strength(NS) | May 17, 2021 |
| M(M-290) | Mar 01, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: Indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years of age and older
Dosage: POWDER
More Information on Dosage
ARNUITY ELLIPTA family patents
10. Auryxia patent expiration
AURYXIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9328133 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| US9757416 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| US8338642 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| US7767851 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8093423 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Apr, 2026
(1 year, 3 months from now) | |
| US5753706 | KERYX BIOPHARMS | Methods for treating renal failure |
Feb, 2022
(2 years ago) | |
| US10300039 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(5 years from now) | |
| US8846976 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| US8901349 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| US8609896 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| US9387191 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(5 years from now) | |
| US8299298 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Feb, 2024
(10 months ago) | |
| US8754258 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| US8754257 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| US9050316 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-790) | Nov 06, 2020 |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorous levels; Control of serum phosphorus levels
Dosage: TABLET
More Information on Dosage
AURYXIA family patents
11. Axumin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5808146 | BLUE EARTH | Amino acid analogs for tumor imaging |
Nov, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9387266 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(1 year, 11 months from now) | |
| US11980674 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Apr, 2042
(17 years from now) | |
| US10716868 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10967077 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10953112 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(1 year, 11 months from now) | |
| US10933147 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10010632 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(1 year, 11 months from now) | |
| US10124079 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using FLUCICLOVINE F-18 ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Method of diagnosing tumors using positron emission tomography; Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate speci...
Dosage: SOLUTION
More Information on Dosage
AXUMIN family patents
12. Brilinta patent expiration
BRILINTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7250419 | ASTRAZENECA | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec, 2019
(5 years ago) | |
| US7265124 | ASTRAZENECA | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul, 2021
(3 years ago) | |
| US6525060 | ASTRAZENECA | Triazolo(4,5-d)pyrimidine compounds |
Dec, 2019
(5 years ago) | |
| US6251910 | ASTRAZENECA | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul, 2018
(6 years ago) | |
| USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6525060 | ASTRAZENECA | Triazolo(4,5-d)pyrimidine compounds |
Dec, 2019
(5 years ago) | |
| US6251910 | ASTRAZENECA | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul, 2018
(6 years ago) | |
| US7250419 | ASTRAZENECA | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec, 2019
(5 years ago) | |
| US7265124 | ASTRAZENECA | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul, 2021
(3 years ago) | |
| US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(11 years from now) | |
| US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(5 years from now) | |
|
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(5 years from now) | |
|
USRE46276 (Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(4 months from now) | |
|
US10300065 (Pediatric) | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jul, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
| New Indication(I-714) | Sep 03, 2018 |
| New Strength(NS) | Sep 03, 2018 |
| New Indication(I-851) | May 28, 2023 |
| New Indication(I-848) | Nov 05, 2023 |
| M(M-283) | May 09, 2025 |
| Pediatric Exclusivity(PED) | Nov 09, 2025 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: Reduction of the rate of thrombotic events in patients with acute coronary syndrome; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspir...
Dosage: TABLET
How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage
BRILINTA family patents
13. Daliresp patent expiration
DALIRESP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(9 months ago) | |
| US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(1 year, 10 months ago) | |
| US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(1 year, 10 months ago) | |
| US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2015
(9 years ago) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(9 months ago) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2016 |
| M(M-208) | Aug 31, 2020 |
| New Dosing Schedule(D-171) | Jan 23, 2021 |
| New Strength(NS) | Jan 23, 2021 |
Drugs and Companies using ROFLUMILAST ingredient
NCE-1 date: 28 February, 2015
Market Authorisation Date: 23 January, 2018
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET
How can I launch a generic of DALIRESP before it's drug patent expiration?
More Information on Dosage
DALIRESP family patents
14. Dexilant patent expiration
DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9145389 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6939971 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
| US6462058 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(1 year, 2 months ago) | |
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
| US7285668 | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(4 years ago) | |
|
US7285668 (Pediatric) | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(4 years ago) | |
|
US6462058 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
|
US6939971 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
| US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(7 years from now) | |
| US8722084 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(1 year, 2 months ago) | |
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
| US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(5 years from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(1 year, 2 months from now) | |
| US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(1 year, 7 months from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 26 days from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(3 years from now) | |
| US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(1 year, 9 months from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 26 days from now) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(8 months ago) | |
|
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(8 months ago) | |
|
US7790755 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(2 years from now) | |
|
US8105626 (Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(2 years from now) | |
|
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(5 years from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months; For the treatment of heartburn associated with symptomatic non-ero...
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage
DEXILANT family patents
15. Dexilant Solutab patent expiration
DEXILANT SOLUTAB's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6462058 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
| US9145389 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
| US7285668 | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(4 years ago) | |
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(1 year, 10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7399485 | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
May, 2018
(6 years ago) | |
|
US6238994 (Pediatric) | TAKEDA PHARMS USA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
Nov, 2019
(5 years ago) | |
|
US7399485 (Pediatric) | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
Nov, 2018
(6 years ago) | |
|
US6939971 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
|
US7285668 (Pediatric) | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(4 years ago) | |
| US6328994 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(5 years ago) | |
| US6939971 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
| US6238994 | TAKEDA PHARMS USA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
May, 2019
(5 years ago) | |
| US7875292 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(5 years ago) | |
| US7431942 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(5 years ago) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(1 year, 2 months ago) | |
|
US6328994 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(5 years ago) | |
|
US7875292 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(5 years ago) | |
|
US7431942 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(5 years ago) | |
|
US6462058 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(1 year, 4 months ago) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 26 days from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 26 days from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(1 year, 2 months from now) | |
| US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(4 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(3 years from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(1 year, 6 months from now) | |
|
US8871273 (Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(3 years from now) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(8 months ago) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
More Information on Dosage
DEXILANT SOLUTAB family patents
16. Emend patent expiration
EMEND's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6096742 | MSD MERCK CO | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
Dosage: FOR SUSPENSION
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
17. Epivir patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004968 | VIIV HLTHCARE | Pharmaceutical compositions containing lamivudine |
Mar, 2018
(6 years ago) | |
|
US5905082 (Pediatric) | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
Nov, 2016
(8 years ago) | |
|
US6004968 (Pediatric) | VIIV HLTHCARE | Pharmaceutical compositions containing lamivudine |
Sep, 2018
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-147) | Mar 23, 2018 |
Drugs and Companies using LAMIVUDINE ingredient
Market Authorisation Date: 17 November, 1995
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EPIVIR family patents
18. Flonase Sensimist Allergy Relief patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | HALEON US HOLDINGS | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858596 | HALEON US HOLDINGS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| US7541350 | HALEON US HOLDINGS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| US8752543 | HALEON US HOLDINGS | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | |
| US8347879 | HALEON US HOLDINGS | Fluid dispensing device |
Jul, 2028
(3 years from now) | |
| US8062264 | HALEON US HOLDINGS | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | |
| US9320862 | HALEON US HOLDINGS | Fluid dispensing device |
Nov, 2024
(a month ago) | |
| US8147461 | HALEON US HOLDINGS | Fluid dispensing device |
Oct, 2028
(3 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Otc use: allergy symptom reliever; Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies; Nasal congestion, runny nose, sneezing, itchy nose, and (itchy water eyes ...
Dosage: SPRAY, METERED
More Information on Dosage
FLONASE SENSIMIST ALLERGY RELIEF family patents
19. Gadavist patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5980864 | BAYER HLTHCARE | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5980864 | BAYER HLTHCARE | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2016
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2016 |
| New Indication(I-688) | Jun 11, 2017 |
| New Indication(I-731) | Apr 27, 2019 |
| New Indication(I-801) | Jul 12, 2022 |
Drugs and Companies using GADOBUTROL ingredient
NCE-1 date: 15 March, 2015
Market Authorisation Date: 18 December, 2013
Treatment: Contrast agent for magnetic resonance imaging
Dosage: SOLUTION
More Information on Dosage
GADAVIST family patents
20. Gilenya patent expiration
GILENYA's oppositions filed in EPO
GILENYA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2019
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004565 | NOVARTIS | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
Sep, 2017
(7 years ago) | |
|
US5604229 (Pediatric) | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Aug, 2019
(5 years ago) | |
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2014
(10 years ago) | |
| US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(7 years from now) | |
| US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(1 year, 3 months from now) | |
| US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(3 years from now) | |
|
US8324283 (Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(1 year, 9 months from now) | |
|
US9187405 (Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(3 years from now) | |
|
US9592208 (Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(7 years from now) | |
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
| New Patient Population(NPP) | May 11, 2021 |
| New Strength(NS) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: Treatment of autoimmune disease; Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod; Treatment of relapsing remitting multiple sclerosis by determining varicel...
Dosage: CAPSULE
How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage
GILENYA family patents
21. Iqirvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
| US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
| US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
| US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
| US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or as monotherapy in patients unable to tolerate u...
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
22. Iressa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5770599 | ASTRAZENECA | Quinazoline derivatives |
May, 2017
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 13, 2018 |
| Orphan Drug Exclusivity(ODE) | Jul 13, 2022 |
| Orphan Drug Exclusivity(ODE-95) | Jul 13, 2022 |
Drugs and Companies using GEFITINIB ingredient
Market Authorisation Date: 13 July, 2015
Treatment: First-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutation...
Dosage: TABLET
More Information on Dosage
IRESSA family patents
23. Jadenu Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-239) | Dec 12, 2021 |
| M(M-241) | Jul 24, 2022 |
| M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 18 May, 2017
Treatment: NA
Dosage: GRANULE
More Information on Dosage
JADENU SPRINKLE family patents
24. Juxtapid patent expiration
JUXTAPID's oppositions filed in EPO
JUXTAPID IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5739135 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Apr, 2015
(9 years ago) | |
| US6492365 | CHIESI | Microsomal triglyceride transfer protein |
Dec, 2019
(5 years ago) | |
| US8618135 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(2 months from now) | |
| US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2015
(9 years ago) | |
| US7932268 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(2 years from now) | |
| US9265758 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(2 months from now) | |
| US9364470 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(2 months from now) | |
| US9433617 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(2 months from now) | |
| US10016404 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(2 months from now) | |
| US9861622 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(2 months from now) | |
| US10555938 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia; Treatment of hypercholesterolemia by decreasing the amount or acti...
Dosage: CAPSULE
More Information on Dosage
JUXTAPID family patents
25. Lexiscan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47351 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(5 years ago) | |
| US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536150 | ASTELLAS | Methods of myocardial perfusion imaging |
Jun, 2019
(5 years ago) | |
| US8470801 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(5 years ago) | |
| US8106029 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(5 years ago) | |
| US7655637 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(5 years ago) | |
| US7683037 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(5 years ago) | |
| US7655636 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(5 years ago) | |
| US7582617 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(5 years ago) | |
| US9289446 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(5 years ago) | |
| US7144872 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(5 years ago) | |
| US6642210 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(5 years ago) | |
| US9085601 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(2 years from now) | |
| US9045519 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(5 years ago) | |
| US8183226 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(5 years ago) | |
| US7183264 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(5 years ago) | |
| US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(2 years ago) | |
| US8133879 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(5 years ago) | |
| USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2013 |
| M(M-194) | Jan 17, 2020 |
Drugs and Companies using REGADENOSON ingredient
NCE-1 date: 10 April, 2012
Market Authorisation Date: 10 April, 2008
Treatment: Method of myocardial imaging; Method for stimulating coronary vasodilation for purposes of imaging the heart; A method of myocardial perfusion imaging and increasing coronary blood flow; Method of pro...
Dosage: SOLUTION
How can I launch a generic of LEXISCAN before it's drug patent expiration?
More Information on Dosage
LEXISCAN family patents
26. Lumason patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5686060 | BRACCO | Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography |
Nov, 2019
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11723869 | BRACCO | Freeze-dried product and gas-filled microvesicles suspension |
May, 2039
(14 years from now) | |
| US10232061 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(13 years from now) | |
| US10335502 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-728) | Mar 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Nov 13, 2022 |
Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions
Dosage: FOR SUSPENSION
More Information on Dosage
LUMASON family patents
27. Lyrica Cr patent expiration
LYRICA CR's oppositions filed in EPO
LYRICA CR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(5 years ago) | |
|
US9144559 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(2 years from now) | |
|
US10022447 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(2 years from now) | |
|
US8945620 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(2 years from now) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(5 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(5 years ago) | |
| US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(1 year, 10 months from now) | |
| US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(1 year, 10 months from now) | |
| US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2020 |
| Pediatric Exclusivity(PED) | Apr 11, 2021 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of LYRICA CR before it's drug patent expiration?
More Information on Dosage
LYRICA CR family patents
28. Macrilen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6861409 | NOVO | Growth hormone secretagogues |
Aug, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192719 | NOVO | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2022 |
| Orphan Drug Exclusivity(ODE-170) | Dec 20, 2024 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: 20 December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION
More Information on Dosage
MACRILEN family patents
29. Myrbetriq Granules patent expiration
MYRBETRIQ GRANULES IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(1 year, 1 month ago) | |
| US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(2 years ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(1 year, 1 month ago) | |
| US10058536 | APGDI | Pharmaceutical composition containing mirabegron |
Mar, 2036
(11 years from now) | |
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(7 months ago) | |
|
US10058536 (Pediatric) | APGDI | Pharmaceutical composition containing mirabegron |
Sep, 2036
(11 years from now) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
MYRBETRIQ GRANULES family patents
30. Nexium 24hr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7411070 | ASTRAZENECA LP | Form of S-omeprazole |
May, 2018
(6 years ago) | |
| US6369085 | ASTRAZENECA LP | Form of S-omeprazole |
May, 2018
(6 years ago) | |
| US5900424 | ASTRAZENECA LP | Omeprazole magnesium salt form |
May, 2016
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6428810 (Pediatric) | ASTRAZENECA LP | Pharmaceutical formulation comprising omeprazole |
May, 2020
(4 years ago) | |
|
US7411070 (Pediatric) | ASTRAZENECA LP | Form of S-omeprazole |
Nov, 2018
(6 years ago) | |
|
US6369085 (Pediatric) | ASTRAZENECA LP | Form of S-omeprazole |
Nov, 2018
(6 years ago) | |
| US6428810 | ASTRAZENECA LP | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(5 years ago) | |
|
US5900424 (Pediatric) | ASTRAZENECA LP | Omeprazole magnesium salt form |
Nov, 2016
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| RTO(RTO) | Mar 28, 2017 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 23 November, 2015
Treatment: Method of treating frequent heartburn by administering an esomeprazole magnesium formulation as claimed; Method of treating frequent heartburn by administering an esomeprazole magnesium trihydrate as ...
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of NEXIUM 24HR before it's drug patent expiration?
More Information on Dosage
NEXIUM 24HR family patents
31. Norditropin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
| US5633352 | NOVO NORDISK INC | Biosynthetic human growth hormone |
May, 2014
(10 years ago) | |
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN family patents
32. Norditropin Flexpro patent expiration
NORDITROPIN FLEXPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(2 years from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(6 years ago) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(9 months from now) | |
| US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US6716198 | NOVO NORDISK INC | Injection device |
Jun, 2021
(3 years ago) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(6 months ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(1 year, 5 months ago) | |
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: Treatment of disorders responsive to growth hormone
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
33. Norditropin Flexpro patent expiration
NORDITROPIN FLEXPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(9 months from now) | |
| US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(6 years ago) | |
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(1 year, 5 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(6 months ago) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(2 years from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: Treatment of disorders responsive to growth hormone
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
34. Norditropin Nordiflex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
| US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(6 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
| US6235004 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN NORDIFLEX family patents
35. Nourianz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7727994 | KYOWA KIRIN | Methods of treating patients suffering from movement disorders |
Jan, 2023
(1 year, 11 months ago) | |
| US7727993 | KYOWA KIRIN | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
Jan, 2028
(3 years from now) | |
| US8318201 | KYOWA KIRIN | Method of stabilizing diarylvinylene compound |
Sep, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...
Dosage: TABLET
More Information on Dosage
NOURIANZ family patents
36. Pepaxto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6992207 | ONCOPEPTIDES AB | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Jun, 2024
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10543274 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
| US11344622 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
| US10285946 | ONCOPEPTIDES AB | Lyophilized preparations of melphalan flufenamide |
Apr, 2032
(7 years from now) | |
| US10869928 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
| US10322182 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
| Orphan Drug Exclusivity(ODE-348) | Feb 26, 2028 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...
Dosage: POWDER
More Information on Dosage
PEPAXTO family patents
37. Saxenda patent expiration
SAXENDA's oppositions filed in EPO
SAXENDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6458924 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(7 years ago) | |
| US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(2 years ago) | |
| US7235627 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(1 year, 5 months ago) | |
|
US6268343 (Pediatric) | NOVO | Derivatives of GLP-1 analogs |
Feb, 2023
(1 year, 9 months ago) | |
|
US8579869 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(11 months ago) | |
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8846618 | NOVO | Stable formulation of modified GLP-1 |
Jun, 2022
(2 years ago) | |
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
|
US8846618 (Pediatric) | NOVO | Stable formulation of modified GLP-1 |
Dec, 2022
(1 year, 11 months ago) | |
|
US9486588 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(2 years ago) | |
|
US8672898 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(2 years ago) | |
|
US6899699 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(2 years ago) | |
| US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(12 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(7 months from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(6 months ago) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(2 years from now) | |
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(9 months from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 29 days from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(9 months from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
|
US8920383 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
|
USRE46363 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(2 years from now) | |
|
US9457154 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(3 years from now) | |
|
US9687611 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(2 years from now) | |
|
US9861757 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(1 year, 6 months from now) | |
|
US9616180 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(1 year, 6 months from now) | |
|
US9775953 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
|
US9108002 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(1 year, 7 months from now) | |
|
US9132239 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(7 years from now) | |
|
US8114833 (Pediatric) | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(1 year, 1 month from now) | |
|
US8684969 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(1 year, 3 months from now) | |
|
US9968659 (Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(12 years from now) | |
|
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(28 days ago) | |
|
US10220155 (Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
| New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity
Dosage: SOLUTION
How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage
SAXENDA family patents
38. Selzentry patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6667314 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Aug, 2021
(3 years ago) | |
| US6586430 | VIIV HLTHCARE | CCR5 modulators |
Dec, 2019
(5 years ago) | |
| US7576097 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6667314 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Aug, 2021
(3 years ago) | |
|
US7576097 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2021
(3 years ago) | |
|
US7368460 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2023
(1 year, 6 months ago) | |
| US6586430 | VIIV HLTHCARE | CCR5 modulators |
Dec, 2019
(5 years ago) | |
| US7368460 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2022
(2 years ago) | |
| US7576097 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2021
(3 years ago) | |
|
US6667314 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Feb, 2022
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2012 |
| New Patient Population(NPP) | Oct 30, 2023 |
| New Product(NP) | Nov 04, 2019 |
| New Strength(NS) | Nov 04, 2019 |
| Pediatric Exclusivity(PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
NCE-1 date: 07 August, 2011
Market Authorisation Date: 04 November, 2016
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
Dosage: TABLET; SOLUTION
How can I launch a generic of SELZENTRY before it's drug patent expiration?
More Information on Dosage
SELZENTRY family patents
39. Soliqua 100/33 patent expiration
SOLIQUA 100/33 IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45313 | SANOFI-AVENTIS US | Exendin variant peptides |
Jul, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9950039 | SANOFI-AVENTIS US | Insulin glargine/lixisenatide fixed ratio formulation |
Dec, 2035
(10 years from now) | |
| US9827379 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(9 months ago) | |
| US9775954 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(9 months ago) | |
| US8992486 | SANOFI-AVENTIS US | Pen-type injector |
Jun, 2024
(6 months ago) | |
| US9011391 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(8 months ago) | |
| US9821032 | SANOFI-AVENTIS US | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(7 years from now) | |
| US10029011 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
Nov, 2030
(5 years from now) | |
| US9561331 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months ago) | |
| US9604009 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(4 months ago) | |
| US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(5 years from now) | |
| US9604008 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(9 months ago) | |
| US9408979 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(9 months ago) | |
| US7918833 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2027
(2 years from now) | |
| US10117909 | SANOFI-AVENTIS US | Combination of an insulin and a GLP-1 agonist |
Oct, 2029
(4 years from now) | |
| US9233211 | SANOFI-AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(9 months ago) | |
| US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(3 months from now) | |
| US9526844 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(9 months ago) | |
| US8603044 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(9 months ago) | |
| US9533105 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(4 months ago) | |
| US9717852 | SANOFI-AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
| US9526764 | SANOFI-AVENTIS US | Combination of an insulin and a GLP-1-agonist |
Oct, 2029
(4 years from now) | |
| US8512297 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2024
(3 months ago) | |
| US8556864 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(9 months ago) | |
| US9623189 | SANOFI-AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(4 months ago) | |
| US9610409 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: Improvement in glycemic control in adults with type 2 diabetes mellitus inadequately controlled by lixisenatide in combination with metformin and a second oral antidiabetic drug; Improvement in glycem...
Dosage: SOLUTION
More Information on Dosage
SOLIQUA 100/33 family patents
40. Spiriva Respimat patent expiration
SPIRIVA RESPIMAT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39820 | BOEHRINGER INGELHEIM | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
Jan, 2018
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6149054 (Pediatric) | BOEHRINGER INGELHEIM | Mechanical counter for a metering apparatus |
Jun, 2017
(7 years ago) | |
| US7246615 | BOEHRINGER INGELHEIM | Atomising nozzle and filter and spray generating device |
May, 2016
(8 years ago) | |
| US7988001 | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Aug, 2021
(3 years ago) | |
| US7104470 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) | |
| US6453795 | BOEHRINGER INGELHEIM | Locking mechanism for a spring-actuated device |
Dec, 2016
(8 years ago) | |
| US6176242 | BOEHRINGER INGELHEIM | Method of treating manic depression by brain infusion |
May, 2016
(8 years ago) | |
|
USRE39820 (Pediatric) | BOEHRINGER INGELHEIM | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
Jul, 2018
(6 years ago) | |
| US5964416 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) | |
| US6726124 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) | |
| US6988496 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2020
(4 years ago) | |
| US6977042 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(6 years ago) | |
|
US6988496 (Pediatric) | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Aug, 2020
(4 years ago) | |
| US6176442 | BOEHRINGER INGELHEIM | Device for mounting a component exposed to a pressurized fluid |
May, 2016
(8 years ago) | |
| US6149054 | BOEHRINGER INGELHEIM | Mechanical counter for a metering apparatus |
Dec, 2016
(8 years ago) | |
|
US6846413 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured filter |
Feb, 2019
(5 years ago) | |
| US6846413 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(6 years ago) | |
|
US5964416 (Pediatric) | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Apr, 2017
(7 years ago) | |
|
US6453795 (Pediatric) | BOEHRINGER INGELHEIM | Locking mechanism for a spring-actuated device |
Jun, 2017
(7 years ago) | |
|
US7104470 (Pediatric) | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Apr, 2017
(7 years ago) | |
|
US6726124 (Pediatric) | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Apr, 2017
(7 years ago) | |
|
US7246615 (Pediatric) | BOEHRINGER INGELHEIM | Atomising nozzle and filter and spray generating device |
Dec, 2016
(8 years ago) | |
|
US6176442 (Pediatric) | BOEHRINGER INGELHEIM | Device for mounting a component exposed to a pressurized fluid |
Dec, 2016
(8 years ago) | |
| US7802568 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2019
(5 years ago) | |
|
US7802568 (Pediatric) | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Aug, 2019
(5 years ago) | |
|
US6977042 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured filter |
Feb, 2019
(5 years ago) | |
|
US7988001 (Pediatric) | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Feb, 2022
(2 years ago) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(1 year, 9 months from now) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(3 years from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(5 months from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(5 years from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(2 years from now) | |
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(3 months ago) | |
|
US7896264 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
Nov, 2025
(11 months from now) | |
|
US7284474 (Pediatric) | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Feb, 2025
(2 months from now) | |
|
US7837235 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2028
(3 years from now) | |
|
US7396341 (Pediatric) | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Apr, 2027
(2 years from now) | |
|
US9027967 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2027
(2 years from now) | |
|
US8733341 (Pediatric) | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 15, 2018 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage
SPIRIVA RESPIMAT family patents
41. Tpoxx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8124643 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9907859 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(6 years from now) | |
| US10576165 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(6 years from now) | |
| US8039504 | SIGA TECHNOLOGIES | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jul, 2027
(2 years from now) | |
| US8530509 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(6 months ago) | |
| US9233097 | SIGA TECHNOLOGIES | ST-246 liquid formulations |
Aug, 2031
(6 years from now) | |
| US8802714 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(6 months ago) | |
| US7737168 | SIGA TECHNOLOGIES | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 13, 2023 |
| Orphan Drug Exclusivity(ODE-200) | Jul 13, 2025 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 13 July, 2022
Market Authorisation Date: 18 May, 2022
Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg
Dosage: SOLUTION
More Information on Dosage
TPOXX family patents
42. Truvada patent expiration
TRUVADA's oppositions filed in EPO
TRUVADA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(7 years ago) | |
| US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(7 years ago) | |
| US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(7 years ago) | |
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(9 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(7 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
| US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(7 years ago) | |
| US6043230 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(7 years ago) | |
| US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(4 years ago) | |
|
US5922695 (Pediatric) | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
|
US5935946 (Pediatric) | GILEAD | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
|
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
|
US5977089 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US6043230 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US8716264 (Pediatric) | GILEAD | Compositions and methods for combination antiviral therapy |
Jul, 2024
(5 months ago) | |
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(9 years ago) | |
| US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(7 years ago) | |
| US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(7 years ago) | |
|
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(3 years ago) | |
|
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(3 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(7 years ago) | |
| US9457036 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months ago) | |
| US9744181 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US8592397 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months ago) | |
| US8716264 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months ago) | |
Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Method of treatment of adults infected with hiv-1; Treatment of hiv; Treatment of hiv infection; Prophylaxis of hiv-1 infe...
Dosage: TABLET
How can I launch a generic of TRUVADA before it's drug patent expiration?
More Information on Dosage
TRUVADA family patents
43. Vascepa patent expiration
VASCEPA's oppositions filed in EPO
VASCEPA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188146 | AMARIN PHARMS | Highly purified ethyl EPA and other EPA derivatives |
Jan, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399446 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8431560 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8501225 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8524698 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8188146 | AMARIN PHARMS | Highly purified ethyl EPA and other EPA derivatives |
Jan, 2020
(4 years ago) | |
| US8377920 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8367652 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8617594 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8445003 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US9700537 | AMARIN PHARMS | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
May, 2027
(2 years from now) | |
| US9198892 | AMARIN PHARMS | Composition and/or method for preventing onset and/or recurrence of cardiovascular events |
Sep, 2027
(2 years from now) | |
| US8410086 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(5 years from now) | |
| US8454994 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8455472 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(5 years from now) | |
| US8617593 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8618166 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
| US8623406 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8642077 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8669245 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(5 years from now) | |
| US8680144 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Feb, 2030
(5 years from now) | |
| US8703185 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8691871 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
| US8709475 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8710041 | AMARIN PHARMS | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy |
Jun, 2030
(5 years from now) | |
| US9603826 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9623001 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9693984 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9693985 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9693986 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US10010517 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US9918954 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US10278936 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US10278937 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US10383840 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US8293728 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8314086 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8318715 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US10555925 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US10555924 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US8551521 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8440650 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8415335 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8563608 | AMARIN PHARMS | Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Apr, 2030
(5 years from now) | |
| US8357677 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US11154526 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
| US10568861 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US10668042 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US10576054 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US11717504 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Apr, 2030
(5 years from now) | |
| US10786478 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US10792267 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
| US10792270 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US10842768 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(5 years from now) | |
| US10842766 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8293727 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US10881632 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US10894028 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US11103477 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US11000499 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US11116742 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US8445013 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8518929 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US11213504 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8298554 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| US8546372 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US8426399 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(5 years from now) | |
| US9610272 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US10278935 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US10265287 | AMARIN PHARMS | Methods of reducing triglycerides and LDL-C |
Apr, 2030
(5 years from now) | |
| US11369582 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US11298333 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
| New Indication(I-819) | Dec 13, 2022 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia; Use of vascepa as an adjunct to statin therapy to reduce the occurrence of a cardiovascular event in an adult patien...
Dosage: CAPSULE
How can I launch a generic of VASCEPA before it's drug patent expiration?
More Information on Dosage
VASCEPA family patents
44. Venlafaxine Besylate patent expiration
VENLAFAXINE BESYLATE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6717015 | ALMATICA | Venlafaxine besylate |
Mar, 2023
(1 year, 8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(3 years from now) | |
Drugs and Companies using VENLAFAXINE BESYLATE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Treatment of depression and generalized anxiety disorder
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VENLAFAXINE BESYLATE family patents
45. Veramyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8752543 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | |
| US6858596 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| US7541350 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| US8062264 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | |
| US9320862 | GLAXOSMITHKLINE | Fluid dispensing device |
Nov, 2024
(a month ago) | |
| US8147461 | GLAXOSMITHKLINE | Fluid dispensing device |
Mar, 2025
(2 months from now) | |
| US8347879 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2027
(2 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: The treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older; Treatment of rhinitis comprising the nasal application of a pharmaceutical formulation a...
Dosage: SPRAY, METERED
More Information on Dosage
VERAMYST family patents
46. Vyvanse patent expiration
VYVANSE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(1 year, 9 months ago) | |
| US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
| US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7671030 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
| US7659254 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
|
US7662788 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
| US7713936 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
|
US7700561 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7723305 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
| US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
| US7687467 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Apr, 2023
(1 year, 8 months ago) | |
| US7723305 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
| US7718619 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
| US7671031 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
| US7662788 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
| US7678770 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(1 year, 8 months ago) | |
| US7105486 | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Jun, 2023
(1 year, 5 months ago) | |
| US7678771 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(1 year, 8 months ago) | |
| US7674774 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(1 year, 9 months ago) | |
| US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
|
US7671030 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7718619 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
| US7700561 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Jun, 2023
(1 year, 5 months ago) | |
| US7687466 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 9 months ago) | |
| US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(1 year, 9 months ago) | |
| US7223735 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Jun, 2023
(1 year, 5 months ago) | |
|
US7662787 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(1 year, 3 months ago) | |
|
US7671031 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7674774 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7713936 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7105486 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Aug, 2023
(1 year, 3 months ago) | |
|
US7223735 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(1 year, 3 months ago) | |
|
US7655630 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7659253 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7659254 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7678770 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7678771 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7687466 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
|
US7687467 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 23, 2012 |
| M(M-82) | Apr 05, 2013 |
| New Patient Population(NPP) | Nov 10, 2013 |
| New Indication(I-645) | Jan 31, 2015 |
| New Indication(I-703) | Jan 30, 2018 |
| M(M-188) | Oct 14, 2019 |
Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient
Market Authorisation Date: 28 January, 2017
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults; Indicated for the treatment of attention-deficit/hyperacti...
Dosage: CAPSULE
How can I launch a generic of VYVANSE before it's drug patent expiration?
More Information on Dosage
VYVANSE family patents
47. Xarelto patent expiration
XARELTO's oppositions filed in EPO
XARELTO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7585860 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(4 years ago) | |
| US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7585860 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(4 years ago) | |
| US7592339 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(4 years ago) | |
| US9415053 | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(a month ago) | |
| US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(14 years from now) | |
|
US7157456 (Pediatric) | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb, 2025
(2 months from now) | |
|
US9415053 (Pediatric) | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
May, 2025
(4 months from now) | |
|
US9539218 (Pediatric) | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Aug, 2034
(9 years from now) | |
|
US10828310 (Pediatric) | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jul, 2039
(14 years from now) | |
| US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-643) | Nov 04, 2014 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Indication(I-662) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-824) | Oct 11, 2021 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-867) | Aug 23, 2024 |
| New Product(NP) | Dec 20, 2024 |
| Pediatric Exclusivity(PED) | Jun 20, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Treatment of venous thromboembolism (vte) and the reduction in the ...
Dosage: TABLET; FOR SUSPENSION
How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage
XARELTO family patents
48. Xeglyze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9839631 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7812163 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Oct, 2026
(1 year, 10 months from now) | |
| US8212038 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(5 months ago) | |
| US10292389 | HATCHTECH | Pediculicidal composition |
Dec, 2034
(9 years from now) | |
| US9357783 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION
More Information on Dosage
XEGLYZE family patents
49. Xepi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6335447 | FERRER INTERNACIONAL | Quinolonecarboxylic acid derivatives or salts thereof |
Nov, 2023
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(4 years from now) | |
| US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: 11 December, 2021
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: CREAM
More Information on Dosage
XEPI family patents
50. Xtoro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6432948 | FONSECA BIOSCIENCES | Use of 7-(2-oxa-5,8-diazabicylco[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of heliobacter pylori infections and associated gastroduodenal diseases |
Apr, 2017
(7 years ago) | |
| US6133260 | FONSECA BIOSCIENCES | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases |
Apr, 2017
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536167 | FONSECA BIOSCIENCES | Methods for treating ophthalmic, otic, or nasal infections |
Aug, 2031
(6 years from now) | |
| US9119859 | FONSECA BIOSCIENCES | Methods for treating otic infections |
Jul, 2030
(5 years from now) | |
| US9993483 | FONSECA BIOSCIENCES | Compositions and methods for treating ophthalmic, octic, or nasal infections |
Jul, 2030
(5 years from now) | |
| US9504691 | FONSECA BIOSCIENCES | Finafloxacin suspension compositions |
Nov, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 17, 2019 |
| Pediatric Exclusivity(PED) | Jun 17, 2020 |
Drugs and Companies using FINAFLOXACIN ingredient
NCE-1 date: 18 June, 2019
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS
More Information on Dosage
XTORO family patents
51. Zontivity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7235567 | KEY THERAP | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
Jun, 2021
(3 years ago) | |
| US7304078 | KEY THERAP | Thrombin receptor antagonists |
Dec, 2027
(3 years from now) | |
| US7713999 | KEY THERAP | Thrombin receptor antagonists |
May, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2019 |
Drugs and Companies using VORAPAXAR SULFATE ingredient
NCE-1 date: 08 May, 2018
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events; Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad)
Dosage: TABLET
More Information on Dosage
ZONTIVITY family patents
52. Zyvox patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(3 years ago) | |
|
US6559305 (Pediatric) | PFIZER | Linezolid—crystal form II |
Jul, 2021
(3 years ago) | |
| US5688792 | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Nov, 2014
(10 years ago) | |
|
US5688792 (Pediatric) | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
May, 2015
(9 years ago) | |
Drugs and Companies using LINEZOLID ingredient
Market Authorisation Date: 18 April, 2000
Treatment: Treatment of microbial infections
Dosage: SOLUTION
How can I launch a generic of ZYVOX before it's drug patent expiration?
More Information on Dosage
ZYVOX family patents